Sangamo TherapeuticsSGMO
Market Cap: $151M
About: Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Employees: 405
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
3% less funds holding
Funds holding: 130 [Q1] → 126 (-4) [Q2]
8.0% less ownership
Funds ownership: 49.83% [Q1] → 41.82% (-8.0%) [Q2]
14% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 29
29% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 45
52% less call options, than puts
Call options by funds: $29K | Put options by funds: $60K
55% less capital invested
Capital invested by funds: $68.5M [Q1] → $31.1M (-$37.5M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target | 592%upside $5 | Buy Reiterated | 22 Aug 2024 |
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target | 592%upside $5 | Buy Reiterated | 31 Jul 2024 |
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target | 592%upside $5 | Buy Reiterated | 24 Jul 2024 |